First author [Ref.] | Previously treated | Previous treatment >1 month | Drugs used | Cohort prevalence of HIV | Linezolid | Definitions# | ||||
MDR | XDR | MDR | XDR | MDR | XDR | MDR | XDR | |||
Gandhi 9 | 21 (45) | 44 (100) | WHO | |||||||
Migliori 10 | 74 (58.7) | 11 (100) | 2¶ | 3¶ | 5.3+ | 5.5+ | 10 (9.2) | 0 (0) | WHO | |
Migliori 11 | 178 (49.3) | 48 (75) | 2.1¶ | 3¶ | 5¶ | 6¶ | 17 (5) | 2 (3.2) | WHO/Laserson | |
Kim 12 | 103 (61.3) | 24 (55.8) | 6¶ | 7¶ | 0 (0) | 0 (0) | Yes | Laserson | ||
Mitnick 16 | 47 (97.9) | 602 (99.8) | 3.2+ | 4.2+ | 5.3 | 9 (1.5) | 0 (0) | Laserson | ||
Chan 17 | ||||||||||
Keshavjee 19 | 574 (95.5) | 29 (100) | 2¶ | 3¶ | 5 (0.9) | 0 (0) | Laserson | |||
Eker 18 | 94 (53) | 6 (86) | 2¶ | 2.4¶ | 4+ | 5+ | 7 (4.9) | 0 (0) | Yes | Laserson |
Kwon 20 | 113 (88) | 24 (89) | 6¶ | 6¶ | 0 (0) | 0 (0) | Laserson | |||
Lai 21 | Microbiological testing | |||||||||
Banerjee 22 | WHO | |||||||||
Bonilla 23 | 88.9§ | 88.5§ | 1.6 | 2 | Laserson | |||||
Kim 24 | 1286 (96) | 73 (97) | 5¶ | 5¶ | 0 (0) | 1 (1.7) | WHO |
Data are presented as n or n (%), unless otherwise stated. MDR: multidrug-resistant; XDR: extensively drug-resistant; WHO: World Health Organization. #: according to Laserson et al. 28 and/or the WHO; ¶: median; +: mean; §: data presented as %.